Abstract: Tumors of the oral cavity are relatively common malignancies with a poor prognosis. Use of both prognostic and predictive biomarkers in saliva represents one approach to improve the management of patients with these cancers. The aim of the present study was to measure salivary neopterin concentrations before and after surgery in patients with oropharyngeal cancer to assess potential use as a biomarker in clinical practice. Salivary neopterin concentration was determined before and after surgery in 16 patients treated for oropharyngeal cancer and compared with 15 healthy volunteers. Salivary neopterin concentrations were significantly higher in patients before surgery compared to the healthy controls. After the surgery, neopterin concentrations decreased significantly, and concentrations in patients and controls were comparable. A significant correlation was observed between the sum of the Community Periodontal Index of Treatment Needs values and salivary neopterin concentrations. In conclusion, tumor removal results in significant decrease of salivary neopterin concentrations. The use of salivary neopterin in diagnosis is compounded by an association with periodontal disease.
Introduction
Tumors of the oral cavity are relatively common malignant neoplasms with poor prognosis. Most of these tumors are characterized by squamous histology. It is estimated that approximately 300,000 new cases were diagnosed worldwide in 2012, giving an age-standardized rate of 4 per 100,000 and estimated mortality rate of 2.7 per 100,000. An increasing trend of incidence has been reported in many parts of the world [1] . These tumors share many features with other head and neck neoplasms, and surgery is the mainstay of therapy [2] . Multidisciplinary management that encompasses surgery, radiotherapy and systemic chemotherapy results in higher cure rates, but also in significant, sometimes life-threatening toxicity [3] . Despite recent improvements, the relapse rate in patients with cancer of the oral cavity is still relatively high. Diversification of therapeutic strategy for individual patients may result in improved outcomes both in terms of efficacy and tolerance of treatment.
A crucial role in the management of cancer patients is played by biomarkers [4] . Proper use of prognostic and predictive biomarkers may allow diversification of therapy resulting in an individualized treatment approach. Although most attention in the past few decades has been focused on biomarkers reflecting the tumor cell properties, biomarkers associated with the host response to neoplasia may be equally important [5] .
Neopterin is a biomarker of cellular immune response [6] . Although increased concentrations of neopterin in the serum or in urine in association with poor prognosis have been reported in many different primary tumors, the information on neopterin in patients with tumors of the head and neck is relatively limited [7] [8] [9] . Even less is known about neopterin concentrations in other body fluids, including saliva [10] [11] [12] [13] [14] [15] [16] . In cancer patients neopterin was studied in ascites [17] [18] [19] or cerebrospinal fluid [20] [21] [22] [23] , but to the best of our knowledge there has been no study of salivary neopterin in patients with head and neck cancer.
The aim of this pilot study was to assess the potential of salivary neopterin as a biomarker in patients with tumors of the oral cavity.
Patients and methods
Twenty-one patients, 13 males and eight females, aged (mean±standard deviation) 62±16 (range 24-88) years, presenting for surgical treatment of cancers of the oral cavity were enrolled in the present study. The patients were staged based on the sixth edition of the tumor-node-metastasis (TNM) classification [24] . Fifteen healthy individuals, seven males and eight females, aged 27±8 (range 23-51) years, served as a control group. The difference in age between patients and controls was statistically significant (p < 0.00001). Dental examination was performed in all subjects studied. All subjects provided informed consent. The present study was approved by the institutional ethical committee.
Part of the initial examination was a standard dental examination, including ortothopantomogram, with extractions of gangrenous teeth and periodontal examinations using the Community Periodontal Index of Treatment Needs (CPITN) was performed as a part of the initial examination. CPITN is a simple rapid screening method of a basic periodontal examination. CPITN represents a qualitative scale that characterizes the condition of the teeth ranging from healthy status, to bleeding after irritation and loss of attachment between gingival and teeth with different depth of teeth pockets [10, 15] . The dentition is divided into six parts (sextants) and the highest score (ranging from 0 to 4) for each sextant is recorded. A sextant must have at least two teeth to be evaluable. The examination is performed with the World Health Organization CPITN calibrated probe with an atraumatic ball end of 0.5 mm. The sum of values from all sextants was subsequently calculated. All extractions were performed preceding the collection of the sample. This eliminated odontogenic and mucosal inflammatory changes in the oral cavity which could increase salivary neopterin concentrations. The sampling of saliva was performed 3 weeks after the teeth extractions and usually 1-2 days before surgery. Subsequent samples were obtained in patients who were not treated with adjuvant chemoradiation that could change salivary neopterin concentrations as a consequence of mucositis or xerostomia.
Approximately 5 mL of saliva was obtained in a dark room before surgery and subsequently after complete healing of the mucosal wound (usually in 6-8 weeks). No specific measures, e.g. chewing gum, were taken before the collection of the specimen. The samples were collected in the morning hours after morning oral hygiene, 30 min after drinking of 200 mL of water, and were subsequently frozen at -25 °C until analysis. Salivary neopterin was measured using an enzyme-linked immunosorbent assay using a commercial kit (IBL International, Hamburg, Germany).
A Mann-Whitney U-test was used to compare salivary neopterin concentrations between the patients and controls, and a Wilcoxon signed rank test was used to compare salivary neopterin concentrations before and after surgery. Correlation was studied using the Spearman's rank correlation coefficient. Values of p < 0.05 were considered statistically significant. The receiver operating characteristics (ROC) method was used to determine the optimal cutoff value of salivary neopterin concentration for predicting the presence of oral cancer. Sensitivity, specificity, positive predictive value, negative predictive value and area under the curve (AUC) (including 95% confidence intervals) for optimal cut-off value were estimated. A ROC curve was constructed. Statistical analyses were performed using IBM SPSS Statistics version 22 software (IBM Corporation, New York, NY, USA).
Results
From the 21 patients studied, pre-operative and post-operative salivary neopterin could be compared in 16 cases. The other five patients were excluded because of postoperative radiotherapy (four cases) or because of benign histology (one patient). In addition, one patient referred for radiotherapy died of thrombembolism. All 16 patients studied before and after treatment had squamous histology (Table 1) .
Pre-operative salivary neopterin concentration was significantly higher in patients compared to controls (8.6±4.8 nmol/L vs. 4.3±1.2 nmol/L in the control group, p = 0.004). Salivary neopterin concentrations in 16 patients decreased significantly after the surgery (8.8±4.8 vs. 5.2±2.6 nmol/L, p = 0.001). In contrast to pre-operative salivary neopterin concentrations, no significant difference was observed in salivary post-operative neopterin concentration compared to the control group (p = 0.353). Salivary neopterin concentrations were not significantly different between males and females and between smokers and non-smokers (data not shown).
The optimal cut-off value for baseline salivary neopterin concentration based on the ROC curve analysis (Figure 1 ) for predicting the presence of oral cancer was 4.95 nmol/L. The AUC was 0.821 (p = 0.002). The sensitivity was 81.3% (95% CI 54.4%-95.9%), and specificity was 66.7% (95% CI 38.4%-88.2%). The positive predictive value was 72.2% (95% CI 46.5%-90.3%), and the negative predictive value was 76.9% (95% CI 46.2%-94.9%) for this cut-off value. No association was observed between tumor stage and neopterin concentration (data not shown). When all 36 investigated subjects were analyzed, a significant correlation was observed between salivary neopterin and the sum of CPITN values (r s = 0.375, p = 0.024). Even stronger correlation between neopterin and CPITN was observed in cancer patients (r s =0.504, p = 0.020; Figure 2 ), but this correlation was absent in the control group (r s = -0.183, p = 0.513).
Discussion
The data of the present pilot study demonstrate a decrease of salivary neopterin concentrations after surgical therapy of cancers of the oral cavity, indicating that tumor control is associated with decrease of immune activation in the microenvironment. The information on salivary neopterin concentrations is very limited [10] [11] [12] [13] [14] [15] [16] , and, to the best of our knowledge, the present study is the first investigation of neopterin in the saliva of patients with cancers of the oral cavity. The present data might be interpreted as indicating that salivary neopterin represents a biomarker of oral cancer. However, the correlation observed between salivary neopterin and CPITN suggests that periodontal disease is also an important factor determining local neopterin concentration, and dental health could be a confounding factor when interpreting increased salivary neopterin concentrations. Moreover, some patients had disorders known to be associated with high systemic neopterin production like inflammatory bowel disease, rheumatoid arthritis and diseases of the thyroid, and salivary neopterin concentrations in these patients could be affected by systemic levels.
The association between periodontal disease and salivary neopterin concentrations is in agreement with the data published earlier [13, 15] . Although it is difficult to compare the data on salivary neopterin concentrations reported in different studies on different patient populations and using different methodologies, the salivary neopterin concentrations in the present cohort of patients are, in general, consistent with the values reported in other studies [13, 14] . However, salivary neopterin concentrations in control groups have shown significant differences, with the mean concentrations reported differing among studies several fold. The mean salivary neopterin concentrations in the present study are higher than reported by Reibnegger et al. [14] or by Evans and Wansbrough-Jones [11] , but lower than reported by Abdel-Haq et al. [10] . Similar salivary neopterin concentrations were reported in control groups by Sfriso et al. [12] and in the report by Vrecko et al. [15] . The above mentioned association of salivary neopterin concentrations with periodontal disease that has also been reported by other investigators could at least partly explain these differences [13, 15] .
As a biomarker of cellular immune response, neopterin is increased across a range of different disorders [6, [25] [26] [27] [28] [29] [30] [31] [32] [33] . In cancer patients, increased neopterin concentrations are associated with the suppression of immune response [17, [34] [35] [36] , and high neopterin concentrations predict inferior prognosis [27, 37, 38] . An increase of neopterin concentrations may be observed during cancer therapy. In a previous study, we have reported an increase of urinary neopterin concentrations in patients with carcinomas of the head and neck during radiotherapy [8, 9] . On the other hand, successful tumor control results in a decrease of systemic neopterin concentrations [39] . Present observation extends these observations also to neopterin concentrations in the microenvironment.
The concept of tumor microenvironment is crucial for the understanding biological behavior of tumors, including cancer of the head and neck region [40] . While serum or urinary neopterin concentrations reflect immune activation on the systemic level, salivary neopterin is reflective more of the situation in the tumor microenvironment. Although the interaction between the tumor and the host response in the tumor microenvironment during the course of the disease or during therapy is crucial for the ultimate outcome, the options to repeatedly assess the host response directly in the tumor microenvironment are for obvious reasons limited to special circumstances. Prior studies have, for example, evaluated the local immune response in patients with malignant ascites [17, 41, 42] . While malignant ascites are associated with advanced disease, the investigation of saliva allows also for the assessment of immune activation of early tumors.
Saliva is composed of salivary gland secretions, cervical fluid from dentogingival sulcus, mucosal transudate, cell detritus, alimentary remnants, nasal and pharyngeal secretions. In the salivary glands the interstitial fluid originating from capillaries enters the ductal system where it is transformed from an isotonic to a hypotonic secretion. Saliva contains mineral ions, peptide, proteins as well as hormones, and plays an important role in mucosal defense, digestion and prevention of caries [43] . The idea to use saliva as a matrix for biomarker measurement is not new, and dozens of potential biomarkers have been identified, including tumor biomarkers [44] [45] [46] [47] . Increased concentrations of tumor biomarkers have been reported in patients with tumors arising outside the head and neck region. For example, Streckfus et al. [47] reported increased concentration of carbohydrate antigen (CA) 15-3 in patients with breast cancer. Tumor biomarkers in saliva have also been studied in patients with the tumors of the oral cavity [45, 46] . In contrast to the reports on salivary biomarker concentrations in patients with a tumor primarily outside the head and neck region, salivary neopterin reflects the tumor microenvironment rather than systemic activity. However, the information on biomarkers associated with the host response in the microenvironment in cancer patients is limited [41] .
The present pilot study obviously has several limitations. In the setting of cancer in the oral cavity, investigation of salivary neopterin concentrations after external beam radiation would be difficult because of xerostomia associated with the treatment. Therefore, in the present study, only patients with tumors that required solely surgical therapy were selected. Only two samples were obtained from each individual in this study, but future investigations should evaluate a sequential course of salivary neopterin concentrations. Similarly to urine, saliva can be sampled repeatedly without any patient discomfort. Thus, sequential salivary neopterin concentrations obtained through more a intense sampling schedule could be investigated in relation to healing and local complications. Also, the investigation of prognostic significance of pre-operative salivary neopterin concentrations that should be performed on a larger cohort of patients would require a much longer follow-up.
In conclusion, present data demonstrate a decrease of salivary neopterin concentrations after radical surgical management of tumors in the oral cavity. Salivary neopterin may represent a biomarker of response in the microenvironment for future studies.
